Cargando…
Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial
PURPOSE: The goal of chemotherapy for metastatic breast cancer (MBC) is to prolong survival and maintain health-related quality of life. This study aimed to evaluate long-term health status of patients with MBC who participated in the phase III randomized SELECT BC trial. METHODS: In the SELECT BC t...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288429/ https://www.ncbi.nlm.nih.gov/pubmed/27517267 http://dx.doi.org/10.1007/s11136-016-1388-1 |
_version_ | 1782504326120341504 |
---|---|
author | Shiroiwa, T. Fukuda, T. Shimozuma, K. Mouri, M. Hagiwara, Y. Doihara, H. Akabane, H. Kashiwaba, M. Watanabe, T. Ohashi, Y. Mukai, H. |
author_facet | Shiroiwa, T. Fukuda, T. Shimozuma, K. Mouri, M. Hagiwara, Y. Doihara, H. Akabane, H. Kashiwaba, M. Watanabe, T. Ohashi, Y. Mukai, H. |
author_sort | Shiroiwa, T. |
collection | PubMed |
description | PURPOSE: The goal of chemotherapy for metastatic breast cancer (MBC) is to prolong survival and maintain health-related quality of life. This study aimed to evaluate long-term health status of patients with MBC who participated in the phase III randomized SELECT BC trial. METHODS: In the SELECT BC trial, patients were randomly allocated to the S-1 or taxane (paclitaxel or docetaxel) arm. Health status was assessed by EQ-5D at pre-treatment, 3 and 6 months after randomization, and every 6 months thereafter to the extent possible. Least square mean scores were assessed to compare EQ-5D index values between groups. Time to deterioration analysis was also performed by defining the minimally important difference of EQ-5D as 0.05 or 0.1. RESULTS: The number of patients for EQ-5D analysis was 175 and 208 in the taxane and S-1 arms, respectively. Least square mean EQ-5D index values up to 60 months were 0.741 (95 % CI [0.713–0.769]) in the taxane arm and 0.748 [0.722–0.775] in the S-1 arm. The EQ-5D index value during PFS up to 12 months in the S-1 was superior to the corresponding index value in the taxane (0.812 [0.789–0.834] vs. 0.772 [0.751–0.792], P = 0.009). Time to deterioration analysis also revealed that S-1 significantly delayed the deterioration of EQ-5D index value during the period before progression (P = 0.002 and 0.003). CONCLUSIONS: Our findings suggest that the EQ-5D index value was higher in patients treated with S-1 during first-line chemotherapy. Considering non-inferiority of S-1 in terms of OS, obtained quality-adjusted life years may be greater in the S-1 arm. |
format | Online Article Text |
id | pubmed-5288429 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-52884292017-02-16 Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial Shiroiwa, T. Fukuda, T. Shimozuma, K. Mouri, M. Hagiwara, Y. Doihara, H. Akabane, H. Kashiwaba, M. Watanabe, T. Ohashi, Y. Mukai, H. Qual Life Res Article PURPOSE: The goal of chemotherapy for metastatic breast cancer (MBC) is to prolong survival and maintain health-related quality of life. This study aimed to evaluate long-term health status of patients with MBC who participated in the phase III randomized SELECT BC trial. METHODS: In the SELECT BC trial, patients were randomly allocated to the S-1 or taxane (paclitaxel or docetaxel) arm. Health status was assessed by EQ-5D at pre-treatment, 3 and 6 months after randomization, and every 6 months thereafter to the extent possible. Least square mean scores were assessed to compare EQ-5D index values between groups. Time to deterioration analysis was also performed by defining the minimally important difference of EQ-5D as 0.05 or 0.1. RESULTS: The number of patients for EQ-5D analysis was 175 and 208 in the taxane and S-1 arms, respectively. Least square mean EQ-5D index values up to 60 months were 0.741 (95 % CI [0.713–0.769]) in the taxane arm and 0.748 [0.722–0.775] in the S-1 arm. The EQ-5D index value during PFS up to 12 months in the S-1 was superior to the corresponding index value in the taxane (0.812 [0.789–0.834] vs. 0.772 [0.751–0.792], P = 0.009). Time to deterioration analysis also revealed that S-1 significantly delayed the deterioration of EQ-5D index value during the period before progression (P = 0.002 and 0.003). CONCLUSIONS: Our findings suggest that the EQ-5D index value was higher in patients treated with S-1 during first-line chemotherapy. Considering non-inferiority of S-1 in terms of OS, obtained quality-adjusted life years may be greater in the S-1 arm. Springer International Publishing 2016-08-12 2017 /pmc/articles/PMC5288429/ /pubmed/27517267 http://dx.doi.org/10.1007/s11136-016-1388-1 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Article Shiroiwa, T. Fukuda, T. Shimozuma, K. Mouri, M. Hagiwara, Y. Doihara, H. Akabane, H. Kashiwaba, M. Watanabe, T. Ohashi, Y. Mukai, H. Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial |
title | Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial |
title_full | Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial |
title_fullStr | Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial |
title_full_unstemmed | Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial |
title_short | Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial |
title_sort | long-term health status as measured by eq-5d among patients with metastatic breast cancer: comparison of first-line oral s-1 and taxane therapies in the randomized phase iii select bc trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288429/ https://www.ncbi.nlm.nih.gov/pubmed/27517267 http://dx.doi.org/10.1007/s11136-016-1388-1 |
work_keys_str_mv | AT shiroiwat longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial AT fukudat longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial AT shimozumak longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial AT mourim longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial AT hagiwaray longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial AT doiharah longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial AT akabaneh longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial AT kashiwabam longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial AT watanabet longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial AT ohashiy longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial AT mukaih longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial |